https://doi.org/10.55788/20e9004c
“What makes our trial relevant? First, we focused on stepwise tapering instead of fixed-dose tapering. Secondly, we used disease-specific targets,” explained Dr Celia Michielsens (Sint Maartenskliniek, the Netherlands). Together with her team, she investigated whether a treat-to-target (T2T) strategy with tapering is non-inferior (with a pre-specified non-inferiority margin of 20%) compared with a T2T strategy without tapering in a randomised, controlled, open-label, non-inferiority trial [1]. All participants used TNF inhibitors and had stable low disease activity for ≥6 months. They were randomised (2:1) to a T2T tapering or no-tapering strategy and were followed for 12 months. Low disease activity was defined as a Psoriatic Arthritis Disease Activity Score (PASDAS) ≤3.2 for PsA, and/or Ankylosing Spondylitis Disease Activity Score (ASDAS) <2.1, and/or judgement of physician and patient.
Of the 81 participants in the tapering group, 52% had PsA and the rest had axSpA. Of the 41 participants in the non-tapering group, 54% had PsA and the rest axSpA. At 12 months, 73% in the non-tapering group and 69% in the tapering group achieved low disease activity. This difference was well below the inferiority margin, thus confirming non-inferiority. At 12 months, 58 (72%) participants of the tapering group were successfully tapered. The only disadvantage of this approach was an increase in the use of other medications in the tapering group, a difference that was statistically significant regarding non-steroidal anti-inflammatory drug use (54% vs 24%; P=0.002). However, the risk of grade 3/4 infections was 46% lower, and the risk of injection site reactions was 23% lower in the tapering compared with the non-tapering group.
Taken together, there was no significant difference between a tapering and a non-tapering approach regarding disease activity. “This might have been because we used not a fixed but an individualised tapering approach,” Dr Michielsen said. Moreover, tapering led to a substantial reduction in TNF inhibitor use.
- Michielsens C, et al. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomized controlled non-inferiority trial. OP0261, EULAR 2022 Congress, 1–4 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« A novel oral treatment possibility for non-radiographic axSpA on the horizon Next Article
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib »
« A novel oral treatment possibility for non-radiographic axSpA on the horizon Next Article
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib »
Table of Contents: EULAR 2022
Featured articles
Late-Breaking Oral Abstracts
TYK2 inhibition: the future of treating lupus erythematosus?
Psoriatic arthritis: significant improvement with bimekizumab
Baricitinib could open the door to oral treatment for juvenile idiopathic arthritis
Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares
Spotlight on Rheumatoid Arthritis
Comorbid depression comes with a profoundly higher mortality risk in RA
Preventive treatment with methotrexate benefits pre-RA patients with arthralgia
Risk factors for dementia in RA patients discovered
VTE in global registry data more common in JAK inhibitor-treated RA patients
Spondyloarthropathies – Novel Developments
How to treat enthesitis in 2022
Baseline cardiovascular risk linked to higher rates of MACE in PsA and PsO patients receiving tofacitinib
Treat-to-target dose reduction effective in spondyloarthritis
A novel oral treatment possibility for non-radiographic axSpA on the horizon
Many RA and PsA patients have problems with their sex life
What Is Hot in Osteoarthritis?
New treatments in osteoarthritis
OA associated with alcohol and drug abuse
Body mass index increase associated with structural changes in knee OA
What Is New in Lupus and Scleroderma
Inhibition of Bruton’s tyrosine kinase: a new way of approaching SLE?
Pregnancies in SLE: many complications for mothers and their unborn children
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement
Antifibrotic therapy with nintedanib is beneficial for patients with negative prognostic factors
Best of the Posters
Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease
High prevalence of fibromyalgia in patients with inflammatory bowel disease
Related Articles
October 27, 2021
Rapid symptom control for UC patients on upadacitinib
April 12, 2022
Upadacitinib effector pathways unravelled
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com